Nimacimab

About Skye Bioscience

Skye Bioscience is a clinical-stage biotech focused on developing next-generation therapeutics for obesity and metabolic diseases by selectively inhibiting the peripheral cannabinoid 1 (CB1) receptor. Its core achievement is the advancement of nimacimab, a potentially first-in-class monoclonal antibody, which demonstrated positive combination data with semaglutide in a Phase 2a trial and recently entered a strategic collaboration with Halozyme. The company's strategy is to clinically validate this differentiated, non-GLP-1 mechanism that aims to improve metabolic health, preserve muscle mass, and offer durable weight loss, positioning it as a complementary therapy in the expansive obesity landscape.

About Skye Bioscience

Skye Bioscience is a clinical-stage biotech focused on developing next-generation therapeutics for obesity and metabolic diseases by selectively inhibiting the peripheral cannabinoid 1 (CB1) receptor. Its core achievement is the advancement of nimacimab, a potentially first-in-class monoclonal antibody, which demonstrated positive combination data with semaglutide in a Phase 2a trial and recently entered a strategic collaboration with Halozyme. The company's strategy is to clinically validate this differentiated, non-GLP-1 mechanism that aims to improve metabolic health, preserve muscle mass, and offer durable weight loss, positioning it as a complementary therapy in the expansive obesity landscape.

Therapeutic Areas